TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33502090

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg, 25 mg)
Number of subjects: 6959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6959

Group type: EXPERIMENTAL
Intervention: Polyvascular disease with kidney dysfunction
Number of subjects: 6959
Study: 35346097

Group type: EXPERIMENTAL
Intervention: Supportive counselling using a positive psychology approach (6 sessions of 45 minutes, 3 times a week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supportive counselling using a positive psychology approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study: 33434212

Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 843
Study: 35499696

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (KD and SD)
Number of subjects: 32
Study: 34800034

Group type: EXPERIMENTAL
Intervention: IANB + IO
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: IANB + PDL
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: IANB + BI
Number of subjects: 160

Group type: COMPARATOR
Intervention: IANB
Number of subjects: 160
Study: 32028395

Group type: EXPERIMENTAL
Intervention: Conventional treatment and antimicrobial photodynamic therapy (PACT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional periodontal treatment
Number of subjects: 20
Study: 33104452

Group type: EXPERIMENTAL
Intervention: Voice bubbling therapy (VBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 24
Study: 34634254

Group type: EXPERIMENTAL
Intervention: Single-dose HPV vaccine
Number of subjects: 4348

Group type: EXPERIMENTAL
Intervention: Two-dose HPV vaccine
Number of subjects: 4348

Group type: EXPERIMENTAL
Intervention: Three-dose HPV vaccine
Number of subjects: 4348
Study: 32739466

Group type: COMPARATOR
Intervention: Citalopram 20 mg/d plus 5 mL placebo syrup every 12 h
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 5 mL of lavender-dodder herbal syrup every 12 h plus placebo tablets once daily
Number of subjects: 56
Study: 35729519

Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol (EE) starting at 11 years old with Growth Hormone (GH)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol (EE) starting at 13 years old with Growth Hormone (GH)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no GH or EE until 15 years old)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol (EE) therapy
Number of subjects: 59
Study: 34074296

Group type: EXPERIMENTAL
Intervention: Genetically elevated Lp(a)
Number of subjects: 1256
Study: 32545618

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 987

Group type: COMPARATOR
Intervention: Frequency Ratio (FR) model
Number of subjects: 987
Study: 34883053

Group type: EXPERIMENTAL
Intervention: ChAd/m1273
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: ChAd/NVX
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: BNT/m1273
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: BNT/NVX
Number of subjects: 1072

Group type: COMPARATOR
Intervention: ChAd/ChAd
Number of subjects: 1072

Group type: COMPARATOR
Intervention: BNT/BNT
Number of subjects: 1072
Study: 35248120

Group type: EXPERIMENTAL
Intervention: Active tDCS combined with conventional rehabilitation therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham tDCS combined with conventional rehabilitation treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Active tDCS and Sham tDCS)
Number of subjects: 100
Study: 35316221

Group type: EXPERIMENTAL
Intervention: UB-612 (100 µg)
Number of subjects: 3935
Study: 33633221

Group type: EXPERIMENTAL
Intervention: Keyhole endoscopy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Large trauma craniotomy
Number of subjects: 72
Study: 34510308

Group type: EXPERIMENTAL
Intervention: IPS intervention
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Higher cognitive function
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Higher motivation to change
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Previous work history
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Higher age
Number of subjects: 720
Study: 32778945

Group type: EXPERIMENTAL
Intervention: Capsaicin stimuli (0, 50, 100, 150, 200 μM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ALS patients (silent aspirators, PAS = 8)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cough spirometry metrics
Number of subjects: 32
Study: 35528160

Group type: EXPERIMENTAL
Intervention: S. boulardii in addition to BQT
Number of subjects: 180

Group type: COMPARATOR
Intervention: BQT
Number of subjects: 180
Study: 34775784

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 7352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7352
Study: 33843602

Group type: EXPERIMENTAL
Intervention: Visual Clot
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard ROTEM tracings
Number of subjects: 35
Study: 32364137

Group type: EXPERIMENTAL
Intervention: Oral sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34273231

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo (0.9% saline plus one drop of methoxyflurane)
Number of subjects: 420
Study: 33277455

Group type: EXPERIMENTAL
Intervention: L-Carnitine (2 g/d orally)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 35872960

Group type: EXPERIMENTAL
Intervention: Nursing healthcare based on the theory of health behavior change integration
Number of subjects: 116

Group type: COMPARATOR
Intervention: Common nursing
Number of subjects: 116
Study: 33522981

Group type: EXPERIMENTAL
Intervention: Tech visits (in-person technology support visits)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Tech packet (participant‐facing technology user guide)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Condition-specific text message check-ins
Number of subjects: 129
Study: 34153798

Group type: EXPERIMENTAL
Intervention: dLAN (<5 lux)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Total darkness (CON)
Number of subjects: 20
Study: 32779843

Group type: EXPERIMENTAL
Intervention: Throat gargles (TG) sampling for CARV detection
Number of subjects: 194
Study: 35236065

Group type: COMPARATOR
Intervention: Health resort treatment (HRT) without iodine-bromine baths (IB)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Health resort treatment (HRT) with iodine-bromine baths (IB)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 74
Study: 33608793

Group type: EXPERIMENTAL
Intervention: Pulse intravenous (IV) methylprednisolone (MEP) defined as ≥ 200 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Single ICD code for SLE
Number of subjects: 34
Study: 35708633

Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sesame seed oil (SSO) treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MSM+SSO combination treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diabetic control, no treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All T2D treatment groups
Number of subjects: 20
Study: 33819055

Group type: EXPERIMENTAL
Intervention: NavSTAR (Navigation Services to Avoid Rehospitalization)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 400
Study: 35430502

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 70
Study: 34259583

Group type: EXPERIMENTAL
Intervention: Pre-return-to-work (PRW) medical consultation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Therapeutic part-time (TPT) work
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Knowledge of PRW medical consultation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Knowledge of TPT work
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Contact with occupational physician
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Level of knowledge and use correlation
Number of subjects: 200
Study: 32252976

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5/5 mg
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg and Tanezumab 2.5/5 mg
Number of subjects: 696
Study: 36105683

Group type: EXPERIMENTAL
Intervention: Contralaterally controlled neuromuscular electrical stimulation (CCNMES)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 31
Study: 32233041

Group type: EXPERIMENTAL
Intervention: Brief goal-focused mentoring program (10 sessions)
Number of subjects: 67
Study: 32022363

Group type: EXPERIMENTAL
Intervention: Enzyme alginogel
Number of subjects: 89

Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 89
Study: 35705450

Group type: EXPERIMENTAL
Intervention: Opioid-free pathway (100 mg gabapentin TID, 15 mg ketorolac Q6 hours, 1 mg scheduled IV acetaminophen Q6 hours)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Opioid treatment (tramadol, hydrocodone-acetaminophen, or oxycodone-acetaminophen)
Number of subjects: 57
Study: 32748501

Group type: EXPERIMENTAL
Intervention: Health coach supervised by a virtual care team
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed learning group (e-platform with psychoeducational materials)
Number of subjects: 0
Study: 35169917

Group type: EXPERIMENTAL
Intervention: Cell-assisted autologous fat transplantation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Autologous fat transplantation alone
Number of subjects: 34
Study: 33303476

Group type: EXPERIMENTAL
Intervention: Audiotape of background music and positive suggestions played for 20 minutes during general anaesthesia.
Number of subjects: 385

Group type: COMPARATOR
Intervention: Blank tape (control group).
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Audiotape of background music and positive suggestions played during general anaesthesia.
Number of subjects: 385
Study: 33196293

Group type: EXPERIMENTAL
Intervention: Sunflower meal (SFM) supplementation
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Medium and high level of crude fibre (MF and HF) diets
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Moderate level of crude fibre intake
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: High level of crude fibre consumption
Number of subjects: 600
Study: 34378199

Group type: EXPERIMENTAL
Intervention: LA ultrasound feature established by LASSO regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined model including LA ultrasound feature and AF duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LA ultrasound feature and AF duration
Number of subjects: 0
Study: 32618252

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) and focal MDA (fMDA)
Number of subjects: 0
Study: 33821999

Group type: EXPERIMENTAL
Intervention: Nurse Led Transitional Care Model
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care services
Number of subjects: 66
Study: 32683384

Group type: EXPERIMENTAL
Intervention: Lingual-based four-cornered flap (Group A)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional triangular flap (Group B)
Number of subjects: 17
Study: 33191772

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1.8 g daily)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 1027
Study: 33176824

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodialysis with high cutoff dialyzer
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous veno-venous hemodiafiltration with high-flux dialyzer
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 70
Study: 32478459

Group type: EXPERIMENTAL
Intervention: CoCr-DP-EES
Number of subjects: 5446

Group type: EXPERIMENTAL
Intervention: PtCr-DP-EES
Number of subjects: 5446

Group type: EXPERIMENTAL
Intervention: PtCr-BP-EES
Number of subjects: 5446

Group type: EXPERIMENTAL
Intervention: CoCr-DP-EES (in complex PCI)
Number of subjects: 5446

Group type: EXPERIMENTAL
Intervention: PtCr-DP-EES (in complex PCI)
Number of subjects: 5446

Group type: EXPERIMENTAL
Intervention: PtCr-BP-EES (in complex PCI)
Number of subjects: 5446
Study: 36075387

Group type: EXPERIMENTAL
Intervention: IPCA hydromorphone with bolus‐only dose (A1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: IPCA hydromorphone with continuous infusion (A2)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Oral extended‐release morphine (B)
Number of subjects: 95
Study: 34350902

Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH+)
Number of subjects: 459
Study: 35228117

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus standardised medical care (CBT+SMC)
Number of subjects: 0
Study: 32720188

Group type: EXPERIMENTAL
Intervention: Samata intervention
Number of subjects: 1840
Study: 33378117

Group type: EXPERIMENTAL
Intervention: Alternative theory about buoyancy (Explanation-First)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Anomalies (Anomalies-First)
Number of subjects: 96
Study: 35112219

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) + Vitamin B12 + Magnesium (Supp)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin B12 + Magnesium (Supp)
Number of subjects: 60
Study: 32513290

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) administered using the Spectra Optia TM Apheresis System, first dose of 1.5 plasma volumes followed by one plasma volume on alternate days or daily for five to seven total treatments.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual empiric treatment for COVID-19 without TPE.
Number of subjects: 120
Study: 35022874

Group type: COMPARATOR
Intervention: Corticosteroid injection (40 mg of triamcinolone acetate solution applied to carpal tunnel)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (applied five times a week for a total of 15 sessions, fluence of 6 j/cm2 for 1 min per point at a wavelength of 830 nm)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups (Corticosteroid and LLLT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Corticosteroid injection and LLLT
Number of subjects: 87
Study: 34562208

Group type: EXPERIMENTAL
Intervention: AlphaWave® l-Theanine (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36197349

Group type: EXPERIMENTAL
Intervention: SNAPPS lecture
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional case presentation (control)
Number of subjects: 26
Study: 34302449

Group type: EXPERIMENTAL
Intervention: 25 mg TERN-101 capsules
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 75 mg TERN-101 capsules
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 150 mg TERN-101 capsules
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 5 mg TERN-101 tablets
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 25 mg TERN-101 tablets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32461104

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune checkpoint blockade (ICB)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Durvalumab treatment arm
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo treatment arm
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: High TMB and immune gene expression profile (GEP)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Low TMB and immune gene expression profile (GEP)
Number of subjects: 149
Study: 34582323

Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine (0-2, 0-6, 0-2-6, 0-1, or 0-11 month schedule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4CMenB vaccine (0-2 month schedule)
Number of subjects: 0
Study: 35356991

Group type: EXPERIMENTAL
Intervention: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment (18.5 mW/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (61.67 mW/cm2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment
Number of subjects: 0
Study: 34247932

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of recombinant human heparan-N-sulfatase (rhHNS) 45 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 17
Study: 35028701

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME) with a vaginal cone at home (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFME) with EMG biofeedback in the hospital (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study: 33486526

Group type: EXPERIMENTAL
Intervention: JUUL System 59 mg/mL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: JUUL System 18 mg/mL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: JUUL System 9 mg/mL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual Brand (UB) cigarettes
Number of subjects: 24
Study: 34883040

Group type: EXPERIMENTAL
Intervention: Premium hearing aids
Number of subjects: 23

Group type: COMPARATOR
Intervention: Entry-level hearing aids
Number of subjects: 23
Study: 32359666

Group type: EXPERIMENTAL
Intervention: Clinician-administered SBIRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e-SBIRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study: 35648674

Group type: EXPERIMENTAL
Intervention: MusiCure music before and during colonoscopy
Number of subjects: 337

Group type: COMPARATOR
Intervention: Standard care (no music)
Number of subjects: 337
Study: 32297783

Group type: EXPERIMENTAL
Intervention: 40 mg lisdexamfetamine dimesylate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 32589449

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHMs)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ongoing clinical trials of CHM interventions
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Randomized trials of CHMs
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sample size of ongoing trials
Number of subjects: 52
Study: 33775153

Group type: EXPERIMENTAL
Intervention: In-person prolonged exposure therapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Telemedicine prolonged exposure therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Both treatment conditions (in-person and telemedicine)
Number of subjects: 151
Study: 34256133

Group type: EXPERIMENTAL
Intervention: Diet 2 (40 g kg−1 WMRP)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Diet 3 (108 CFU g−1 LP)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Diet 4 (40 g kg−1 WMRP + 108 CFU g−1 LP)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control (Diet 1: 0 g kg−1 WMRP and 0 CFU g−1 L. plantarum)
Number of subjects: 320
Study: 34432975

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (vaccine)
Number of subjects: 6861

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine and amodiaquine (chemoprevention)
Number of subjects: 6861

Group type: EXPERIMENTAL
Intervention: Combination of RTS,S/AS01E and chemoprevention
Number of subjects: 6861

Group type: COMPARATOR
Intervention: Combination vs Chemoprevention
Number of subjects: 6861

Group type: COMPARATOR
Intervention: Combination vs Vaccine
Number of subjects: 6861
Study: 33103954

Group type: EXPERIMENTAL
Intervention: micro-LED device (group aBL) for 3 and 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: calcium hydroxide (group CH) for 3 and 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: normal saline (group NS) for 3 and 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: continuous low-level aBL exposure
Number of subjects: 30
Study: 33553973

Group type: EXPERIMENTAL
Intervention: Capsule FMT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Antibiotics+enema FMT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 40
Study: 35813432

Group type: EXPERIMENTAL
Intervention: Proprioception and balance training combined with continuous nursing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous nursing
Number of subjects: 60
Study: 33587500

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Tenofovir Alafenamide-based regimens
Number of subjects: 134
Study: 32711855

Group type: COMPARATOR
Intervention: High LCSB consumers (≥12 servings/wk)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Decrease in LCSB consumption
Number of subjects: 476

Group type: COMPARATOR
Intervention: Change in LCSB intake
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: LCSB consumption
Number of subjects: 476
Study: 34487167

Group type: EXPERIMENTAL
Intervention: Active Brains-Fitbit (AB-F) for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP) educational control for 8 weeks
Number of subjects: 19
Study: 33625196

Group type: EXPERIMENTAL
Intervention: Spiral Ganglion (SG) frequency-to-place map
Number of subjects: 11

Group type: COMPARATOR
Intervention: Organ of Corti (OC) place-based map
Number of subjects: 11
Study: 34971577

Group type: EXPERIMENTAL
Intervention: Itacitinib plus corticosteroids
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo plus corticosteroids
Number of subjects: 439
Study: 34190405

Group type: EXPERIMENTAL
Intervention: PediCARE intervention (providing transportation and groceries)
Number of subjects: 9